Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

Company Announcement - Anixa Biosciences appoints Suyasha Gupta as Senior Director of Clinical Development to oversee Phase 1 breast cancer vaccine, Phase 1 ovarian cancer CAR-T therapy, and upcoming Phase 2 breast cancer vaccine trials [1] - Suyasha Gupta brings extensive experience in late-stage oncology and hematology clinical trials, previously managing Phase 2 and 3 studies at Genentech [2] - Dr Pamela Garzone highlights Gupta's expertise in oncology and late-stage clinical trials as critical for advancing Anixa's pipeline [3] Clinical Development Strategy - Anixa's breast cancer vaccine Phase 2 trial will focus on a therapeutic approach rather than prevention, aiming for faster regulatory approval and cost-effectiveness [4] - The vaccine targets α-lactalbumin, a "retired" protein present in certain breast cancers, with an adjuvant to activate an innate immune response [5] - Initial Phase 1 data showed no safety concerns and protocol-defined immune responses in a majority of patients [6] Collaborations and Funding - Anixa collaborates with Cleveland Clinic on the breast cancer vaccine Phase 1 trial, funded by a U S Department of Defense grant [6] - The vaccine technology was invented by Dr Vincent Tuohy, with Cleveland Clinic exclusively licensing it to Anixa [7][8] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio including ovarian cancer immunotherapy and breast cancer vaccines [9] - The company partners with renowned research institutions like Cleveland Clinic and Moffitt Cancer Center for development and commercialization [9]